Roughly a quarter of 38 viral samples from people treated with Xofluza had mutations in their genomes that made the pathogens less susceptible to the drug.

REGN-EB3 and mAb114 reduced mortality in a clinical trial carried out during the ongoing outbreak in Democratic Republic of Congo.

A new study finds that more than 200 human-targeted, non-antibiotic drugs inhibit the growth of bacterial species that make up part of the human microbiome.

One dose of the medication, called Xofluza, cripples influenza by interfering with an enzyme critical for viral replication.  

T-cell therapies are not just for cancer. Researchers are also advancing immunotherapy methods to protect bone marrow transplant patients from viral infections. 

Some viral pathogens modify chromatin and other epigenetic machinery, making them appealing drug targets.

Another case of HIV remission emerges, this time in a South African girl diagnosed as an infant and disease-free for more than eight years.

Human monoclonal antibodies induced during Ebola infection are able to neutralize related viral species, scientists show. 

The short interfering RNA-based therapy TKM-Ebola protects monkeys from the viral strain still circulating in West Africa.